Clinical and Microbiological Outcomes of Ceftazidime-Avibactam Treatment in Adults with Gram-Negative Bacteremia: A Subset Analysis from the Phase 3 Clinical Trial Program.
John E MazuskiFlorian M E WagenlehnerAntoni TorresYehuda CarmeliJoseph W ChowDalia WajsbrotGregory G StonePaurus IraniDavid BharuchaKaren ChengMargaret TawadrousPublished in: Infectious diseases and therapy (2021)
This analysis provides supportive evidence of the efficacy and safety of ceftazidime-avibactam in patients with Gram-negative bacteremia associated with cIAI, cUTI/pyelonephritis, or HAP/VAP.